Caisse DE Depot ET Placement DU Quebec Has $58 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Caisse DE Depot ET Placement DU Quebec grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 149.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 174,569 shares of the company's stock after acquiring an additional 104,705 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned 0.56% of Medpace worth $57,997,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. R Squared Ltd acquired a new position in Medpace during the 4th quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace in the 4th quarter valued at $31,000. Jones Financial Companies Lllp raised its stake in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC grew its stake in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Down 1.5 %

Shares of Medpace stock traded down $4.62 during trading hours on Monday, reaching $300.49. 297,226 shares of the company's stock were exchanged, compared to its average volume of 343,201. The firm has a market capitalization of $8.64 billion, a price-to-earnings ratio of 23.79, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. The company has a fifty day moving average of $309.90 and a 200-day moving average of $330.04. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter last year, the firm earned $3.20 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent research reports. Robert W. Baird reduced their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Mizuho cut their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Truist Financial decreased their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $349.30.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at $904,856.36. This represents a 36.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.